Mutation Genes in Common Tumors of Digestive System and Druggability of New Targets
10.3971/j.issn.1000-8578.2022.21.0938
- VernacularTitle:消化系统常见肿瘤突变基因分析及新靶点成药性评估
- Author:
Xiaojun JI
1
;
Lei MIAO
;
Changyou MA
;
Ying TANG
;
Qiuhua ZHOU
;
Jian WU
;
Dan XU
Author Information
1. Innovation Department of The Research Institute, Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd, Nanjing 210046, China
- Publication Type:Research Article
- Keywords:
Digestive system tumors;
Driver genes;
Mutant genes;
Targets;
Druggability;
New drugs
- From:
Cancer Research on Prevention and Treatment
2022;49(4):340-346
- CountryChina
- Language:Chinese
-
Abstract:
Objective To establish a druggability evaluation method for new targets of anti-tumor drugs by analyzing the mutation genes of common tumors in the digestive system. Methods We collected the mutant gene data of the five common tumors of the digestive system (esophageal cancer, gastric cancer, colorectal cancer, liver cancer and pancreatic cancer) in the Integrative Onco Genomics database, and screened out the genes with higher mutation rates in each tumor. We evaluated the druggability of these genes or their encoded proteins, and discovered the potential targets for the new anti-tumor drugs. Results A total of five tumors, 35 cohorts and 5445 tumor samples were collected in this study. The top 10 mutation genes were selected for further analysis. The canSAR database was used to analyze the druggability of unpublished mutant genes or their encoded proteins, and a total of 17 potential therapeutic drug targets were screened out. Conclusion A method for evaluating druggability of targets based on mutant genes or their encoded protein is established in this study. The application of this method can provide a reference for discovering new anti-tumor therapeutic target, saving the cost and time of target screening in new drug development.
